Surfing MASH’s Post

Orexa Announces First Patient Dosed in Phase 2 Trial in Post-Operative Patients   HERPEN, THE NETHERLANDS, January 19, 2024 - Orexa B.V., a Dutch life sciences company that is developing a new medicine that increases food intake and supports health in patients, announces that the first patient has been dosed in a Phase 2 clinical trial in the prevention of postoperative ileus. The trial investigates whether patients who undergo major abdominal surgery will develop less gastrointestinal disturbances and will recover more quickly.   Study 2022-503113-31-00-IN-002 (EudraCT number) is a multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of Orexa’s lead compound ORE-001. It will enroll 100 to 120 female patients who undergo gynecologic surgery requiring longitudinal laparotomy. The study runs at multiple centers in Germany with lead investigator Prof. Alexander Mustae from Universitätsklinikum Bonn (UKB). The first patient is dosed on 11 January 2024 in Bonn.   “This is a major milestone for a company like Orexa to start its first clinical Phase 2 study,” says Prof. Ard Peeters. He continues: “Finally we will be able to test our drug in patients. This first study is in a group where we can possibly prevent a so-called postoperative ileus. This is a serious complication, which affects up to 50% of patients in several patient groups and leads to patients being unable to eat and therefore recovering more slowly, resulting in prolonged hospitalization."   #Orexa #Phase2 #ORE-001   About Orexa: Orexa is developing a drug that increases food intake. The markets where increased food intake can lead to substantial health benefits are large. Orexa focuses primarily on the recovery of patients who have undergone surgery, anorexia patients and people with malnutrition (sarcopenia / cachexia). The company is founded in 2016 and is based in Herpen (North Brabant), The Netherlands. For more information, see www.orexa.eu.

The MHRA has just approved vamorolone, an alternative to corticosteroids, in Duchenne muscular dystrophy, for patients 4 years and older, independent of mutation and ambulatory status. Vamorolone has been developed by Santhera Pharmaceuticals and appears to have the same efficacy as glucocorticoids, without associated side effects -- notably on bone growth. This follows the FDA approval in November 2023 (in patients >= 2 years). Vamorolone has also just been approved in the EU (January 2024). The approvals are based off the randomized clinical trial (double-blind, placebo- and prednisone-controlled, multicenter study, on n=121 boys) data that can be consulted here: https://lnkd.in/gbNC47H2 #duchennemusculardystrophy #rarediseases #mhra

New clinical trial results indicate a promising new strategy for managing high blood pressure. The KARDIA-2 trial found that a single subcutaneous injection of zilebesiran, an experimental drug from Roche and Alnylam Pharmaceuticals, led to improved blood pressure reduction lasting up to 6 months. This is great news for patients who struggle with persistent mild to moderate high blood pressure despite taking medication. Zilebesiran has the potential to be a powerful new tool in the fight against high blood pressure, potentially reducing the need for daily pills. #bloodpressure #clinicaltrials #healthcare

💥 Business is booming for GLP-1 drugs (#Ozempic and #Weygovy) for #diabetes and #WeightLoss... with new GLP-1 indications expanding into #LiverDisease, do we still need drugs for steatotic liver disease? ✅ “The answer is unequivocally yes,” the late Dr. Stephen A. Harrison, previously told Healio. “These drugs do not impact fibrosis to any significant degree — if they do, they take forever to get there.” With the recent FDA approval of Madrigal Pharmaceuticals #resmetirom specifically for the treatment of #MASLD and #MASH, physicians who manage liver diseases are debating over whether (and how) GLP-1s still fit in the treatment pipeline 🚰 In this month’s Healio Exclusive, two #hepatologists — Dr. Rohit Loomba, and Dr. Arul Sanyal — square off with two #endocrinologists — Dr. Rita Basu and Scott Isaacs, MD, FACP, FACE — to offer their unique insights on how each specialty can best leverage the benefits of GLP-1s for the treatment of MASH. ❓ Where do you stand on GLP-1s for liver disease? Join the conversation 💬

Have you ever thought... "This is really a pain in the _____?" Well, there's promising news for those who suffer from acute pain. Vertex Pharmaceuticals has reported very encouraging results for the trials of VX-548, a non-opioid pain medication. Imagine the possibilities and impact this could have on pain management. 💊 As healthcare professionals, we are always looking for new and innovative ways to help our patients. I am hopeful for what this could mean for the future. #healthcareinnovation #sciencenews #pharma #nursesonlinkedin #painmanagement #changemakers

The Study Highlights Aspiration Pneumonia Risk During Endoscopic Procedures in Patients Using GLP-1 Treatments like Ozempic GLP-1 diabetes and obesity treatments, such as Ozempic, may increase the risk of aspiration pneumonia in patients undergoing endoscopic procedures. The overall risk is low at 0.83% but is 33% higher than for non-users. The risk is even higher for specific procedures and sedated patients. Further research is needed to understand the effects of newer GLP-1 medications. The study highlights the need for increased awareness and preventive measures when treating patients on GLP-1 drugs. For more details please click the link! https://lnkd.in/gMnXfahM #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

Daratumumab-Based Regimen Shows Efficacy in All Patients With Multiple Myeloma, Regardless of Cytogenic Risk: The benefits of the daratumumab-based regimen were seen in all patients, including those with high and standard cytogenic risk levels. #finance #pharmacy #lifesciences

Madrigal's NASH cirrhosis drug trial completes enrollment, potentially offering first-ever treatment. Resmetirom shows promise in addressing urgent need for liver disease therapy. Learn about this groundbreaking study's impact. For daily news and analysis subscribe to the https://lnkd.in/gFNEJAhc newsletter. #Pharmaceuticals #Healthcare #Biotech

As per DelveInsight Business Research LLP, the Primary Biliary Cholangitis Market size was found to be USD 1.1 billion in 2022 in the 7MM, and it is anticipated to grow at a significant CAGR by 2032. Leading pharma and biotech companies such as Ipsen, Zydus Therapeutics, Calliditas Therapeutics, CymaBay Therapeutics, Mirum Pharmaceuticals, Inc., Intercept Pharmaceuticals, Escient Pharmaceuticals, Inc., GSK, and others are developing novel Primary Biliary Cholangitis drugs. Learn More: https://lnkd.in/g6XuXgMv #healthcare #biotechnology #lifesciences #pharmaceuticalindustry #pharmaceutical #marketresearch #marketforecast #markettrends #consulting #healthcareconsulting #consultingservices #marketforecast

Cardio-Renal-Metabolic (CRM) syndrome involves intricate interconnections between diseases within the body's complex systems. This highlights the immense challenges faced by physicians in cardiology, nephrology, endocrinology, hepatology, and primary medicine. At LAVAA, we are dedicated to assisting modern medical systems by preparing advanced engines designed to integrate seamlessly with medical records. These engines will empower physicians to prevent, diagnose early, and treat CRM syndrome with greater accuracy and efficiency. In collaboration with a leading European pharmaceutical company, we are committed to revolutionizing healthcare. Together, we aim to enhance patient outcomes and drive forward the future of medical innovation. #Pharma #Pharmaceutical #CRM #Cardiovascular #Renal #Metabolic